Scholarlink

Background <p>VEXAS syndrome is a recently recognized, acquired monogenic adult onset hemato-inflammatory syndrome characterized by somatic mutations within the <i>UBA1</i> gene. The acronym VEXAS stands for vacuoles, E1 enzyme, X-linked inheritance, autoinflammatory tendencies, and somatic mutations. It presents as a severe progressive disease displaying varied characteristics that bridge hematologic and rheumatologic domains. Herein, we describe a series with a detailed evaluation of 11 cases of VEXAS syndrome.</p> Materials and methods <p>A comprehensive retrospective analysis of patients diagnosed with VEXAS syndrome over the last 5 years (2020–2025) was conducted. Data on clinical presentation, histopathological findings, genetic characteristics, and outcomes were recorded for systematic characterization.</p> Results <p>A total of 11 cases of VEXAS syndrome were identified. All the patients were males with an age range from 42 to 77 years. Prominent clinical characteristics included history of fever (11), arthritis/arthralgia (10), inflammatory skin lesions (7), vasculitis (6), ocular inflammatory conditions (6), relapsing polychondritis (6), unprovoked venous thrombosis (5), and auricular chondritis (4). Persistent unexplained cytopenia was present in all the patients, manifesting as anemia (10, 8 of which were macrocytic), thrombocytopenia (4), and neutropenia (2). Bone marrow examination was performed in nine cases, five showed morphologic dysplasia. Furthermore, all nine cases characteristically showed cytoplasmic vacuolations in hematopoietic precursors. UBA1 somatic mutations included p.Met41Thr (c.122 T&gt;C Exon 3) (55%), p.Met41Val (c.121 A&gt;G Exon 3) (27%), p.Met41Leu (c.121 A&gt;C Exon 3) (9%), and a variant in the acceptor splice site of Exon 3 (c.118 G&gt;C) (9%). p.Met41Val is associated with inferior overall survival (OS).</p> Conclusion <p>This study characterizes the clinical, morphologic, and laboratory features of VEXAS syndrome and presents the first comprehensive patient cohort from India. With a complex and heterogeneous clinical profile, awareness of the disease is particularly essential among hematologists, rheumatologists, and dermatologists for accurate diagnosis and management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

VEXAS syndrome: a comprehensive clinicopathologic and genetic analysis of a predominantly Indian cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月16日

查看全文
  • Dheeraj Chinnam,
  • Aadya Kerkar,
  • Rohit Gulati,
  • Prateek Bhatia,
  • Sreejesh Sreedharanunni,
  • Praveen Sharma,
  • Minu Singh,
  • Shikha Shah,
  • Narayanan Baskaran,
  • Ramya Puligari,
  • Neha Avtarkrishan Ganju,
  • Prakashini Mruthyunjaya,
  • Lekshmon K.S.,
  • Anuradha Bishnoi,
  • Dipanker De,
  • Sarath Chandra Mouli Veeravalli,
  • Vishvdeep Khushoo,
  • Avtar Krishan Ganju,
  • Prasanta Padhan,
  • Paul Antony,
  • Vikas Gupta,
  • Anand Balakrishnan,
  • Arushi Sharma,
  • Dikshat Gopal Gupta,
  • Aman Sharma,
  • Pankaj Malhotra

摘要

Background

VEXAS syndrome is a recently recognized, acquired monogenic adult onset hemato-inflammatory syndrome characterized by somatic mutations within the UBA1 gene. The acronym VEXAS stands for vacuoles, E1 enzyme, X-linked inheritance, autoinflammatory tendencies, and somatic mutations. It presents as a severe progressive disease displaying varied characteristics that bridge hematologic and rheumatologic domains. Herein, we describe a series with a detailed evaluation of 11 cases of VEXAS syndrome.

Materials and methods

A comprehensive retrospective analysis of patients diagnosed with VEXAS syndrome over the last 5 years (2020–2025) was conducted. Data on clinical presentation, histopathological findings, genetic characteristics, and outcomes were recorded for systematic characterization.

Results

A total of 11 cases of VEXAS syndrome were identified. All the patients were males with an age range from 42 to 77 years. Prominent clinical characteristics included history of fever (11), arthritis/arthralgia (10), inflammatory skin lesions (7), vasculitis (6), ocular inflammatory conditions (6), relapsing polychondritis (6), unprovoked venous thrombosis (5), and auricular chondritis (4). Persistent unexplained cytopenia was present in all the patients, manifesting as anemia (10, 8 of which were macrocytic), thrombocytopenia (4), and neutropenia (2). Bone marrow examination was performed in nine cases, five showed morphologic dysplasia. Furthermore, all nine cases characteristically showed cytoplasmic vacuolations in hematopoietic precursors. UBA1 somatic mutations included p.Met41Thr (c.122 T>C Exon 3) (55%), p.Met41Val (c.121 A>G Exon 3) (27%), p.Met41Leu (c.121 A>C Exon 3) (9%), and a variant in the acceptor splice site of Exon 3 (c.118 G>C) (9%). p.Met41Val is associated with inferior overall survival (OS).

Conclusion

This study characterizes the clinical, morphologic, and laboratory features of VEXAS syndrome and presents the first comprehensive patient cohort from India. With a complex and heterogeneous clinical profile, awareness of the disease is particularly essential among hematologists, rheumatologists, and dermatologists for accurate diagnosis and management.